Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease

被引:327
作者
Grammas, Paula [1 ,1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Neurol, Lubbock, TX 79430 USA
基金
美国国家卫生研究院;
关键词
BLOOD-BRAIN-BARRIER; VASCULAR RISK-FACTORS; AMYLOID-BETA-PEPTIDE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; MOUSE MODEL; CELL-DEATH; CEREBRAL MICROVASCULATURE;
D O I
10.1186/1742-2094-8-26
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Alzheimer's disease (AD) is an age-related disorder characterized by progressive cognitive decline and dementia. Alzheimer's disease is an increasingly prevalent disease with 5.3 million people in the United States currently affected. This number is a 10 percent increase from previous estimates and is projected to sharply increase to 8 million by 2030; it is the sixth-leading cause of death. In the United States the direct and indirect costs of Alzheimer's and other dementias to Medicare, Medicaid and businesses amount to more than $172 billion each year. Despite intense research efforts, effective disease-modifying therapies for this devastating disease remain elusive. At present, the few agents that are FDA-approved for the treatment of AD have demonstrated only modest effects in modifying clinical symptoms for relatively short periods and none has shown a clear effect on disease progression. New therapeutic approaches are desperately needed. Although the idea that vascular defects are present in AD and may be important in disease pathogenesis was suggested over 25 years ago, little work has focused on an active role for cerebrovascular mechanisms in the pathogenesis of AD. Nevertheless, increasing literature supports a vascular-neuronal axis in AD as shared risk factors for both AD and atherosclerotic cardiovascular disease implicate vascular mechanisms in the development and/or progression of AD. Also, chronic inflammation is closely associated with cardiovascular disease, as well as a broad spectrum of neurodegenerative diseases of aging including AD. In this review we summarize data regarding, cardiovascular risk factors and vascular abnormalities, neuro-and vascular-inflammation, and brain endothelial dysfunction in AD. We conclude that the endothelial interface, a highly synthetic bioreactor that produces a large number of soluble factors, is functionally altered in AD and contributes to a noxious CNS milieu by releasing inflammatory and neurotoxic species.
引用
收藏
页数:12
相关论文
共 184 条
[1]   Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].
Aisen, PS ;
Schafer, KA ;
Grundman, M ;
Pfeiffer, E ;
Sano, M ;
Davis, KL ;
Farlow, MR ;
Jin, S ;
Thomas, RG ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826
[2]   Inflammation and Alzheimer's disease [J].
Akiyama, H ;
Barger, S ;
Barnum, S ;
Bradt, B ;
Bauer, J ;
Cole, GM ;
Cooper, NR ;
Eikelenboom, P ;
Emmerling, M ;
Fiebich, BL ;
Finch, CE ;
Frautschy, S ;
Griffin, WST ;
Hampel, H ;
Hull, M ;
Landreth, G ;
Lue, LF ;
Mrak, R ;
Mackenzie, IR ;
McGeer, PL ;
O'Banion, MK ;
Pachter, J ;
Pasinetti, G ;
Plata-Salaman, C ;
Rogers, J ;
Rydel, R ;
Shen, Y ;
Streit, W ;
Strohmeyer, R ;
Tooyoma, I ;
Van Muiswinkel, FL ;
Veerhuis, R ;
Walker, D ;
Webster, S ;
Wegrzyniak, B ;
Wenk, G ;
Wyss-Coray, T .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421
[3]   THROMBIN ACCUMULATION IN BRAINS OF PATIENTS WITH ALZHEIMERS-DISEASE [J].
AKIYAMA, H ;
IKEDA, K ;
KONDO, H ;
MCGEER, PL .
NEUROSCIENCE LETTERS, 1992, 146 (02) :152-154
[4]   Restraining tumor necrosis factor-alpha by thalidomide prevents the Amyloid beta-induced impairment of recognition memory in mice [J].
Alkam, Tursun ;
Nitta, Atsumi ;
Mizoguchi, Hiroyuki ;
Saito, Kuniaki ;
Seshima, Mitsuru ;
Itoh, Akio ;
Yamada, Kiyofumi ;
Nabeshima, Toshitaka .
BEHAVIOURAL BRAIN RESEARCH, 2008, 189 (01) :100-106
[5]   The vascular contribution to Alzheimer's disease [J].
Altman, Robin ;
Rutledge, John C. .
CLINICAL SCIENCE, 2010, 119 (9-10) :407-421
[6]  
Andjelkovic AV, 1998, J NEUROSCI RES, V51, P423, DOI 10.1002/(SICI)1097-4547(19980215)51:4<423::AID-JNR2>3.0.CO
[7]  
2-E
[8]  
ARAKI K, 1991, JPN J PSYCHIAT NEUR, V45, P85
[9]   Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-α and TGF-β1 [J].
Araujo, F. A. ;
Rocha, M. A. ;
Mendes, J. B. ;
Andrade, S. P. .
BIOMEDICINE & PHARMACOTHERAPY, 2010, 64 (01) :29-34
[10]   Identification of thrombin receptors in rat brain capillary endothelial cells [J].
Bartha, K ;
Dömötör, E ;
Lanza, F ;
Adam-Vizi, V ;
Machovich, R .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2000, 20 (01) :175-182